Influence of age and gender on risperidone plasma concentrations

Journal of Psychopharmacology

Volumn 19, Issue 4, 2005, Pages 395-401

  Aichhorn, Wolfgang ^a,b   Weiss, Ulrike ^a   Marksteiner, Josef ^a   Kemmler, Georg ^a   Walch, Thomas ^a   Zernig, Gerald ^a   Stelzig Schoeler, Renate ^b   Stuppaeck, Christoph ^b   Geretsegger, Christian ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PMU Salzburg ^*  (Austria)

Author keywords

9 hydroxyrisperidone; Elderly; Gender; Herapeutic drug monitoring; Plasma concentration; Risperidone

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ADULT; AGE; AGED; ARTICLE; DEMENTIA; DRUG BLOOD LEVEL; DRUG MONITORING; ELECTROCHEMICAL DETECTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PREMENOPAUSE; PRIORITY JOURNAL; PSYCHOSIS; SAMPLING; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROCHEMISTRY; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; SEX CHARACTERISTICS;

EID: 13844251076     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105053306     Document Type: Article

References (38)

1. Balant-Gorgia A E, Gex-Fabry M, Genet C, Balant L P (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 21: 105-115
2. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F (2003) A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64: 134-143
3. Carrillo J A, Herraiz A G, Ramos S I, Gervasini G, Vizcaino S, Benitez J (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23: 119-127
4. Catlow J T, Barton R D, Clemens M, Gillespie T A, Goodwin M, Swanson S P (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 668: 85-90
5. Catterson M L, Preskorn S H, Martin R L (1997) Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 20: 205-218
6. Chandler M H, Scott S R, Blouin R A (1988) Age-associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 43: 436-441
7. Chouinard G, Arnott W (1993) Clinical review of risperidone. Can J Psychiatry 38 (Suppl. 3): S89-S95
8. Dawling S, Crome P (1989) Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 17: 236-263
9. Fang J, Bourin M, Baker G B (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151
10. Fletcher C V, Acosta E P, Strykowski J M (1994) Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 15: 619-629
11. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51: 169-173
12. Haring C, Humpel C, Auer B, Saria A, Barnas C, Fleischhacker W, Hinterhuber H (1988) Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 428: 160-166
13. Harris R Z, Benet L Z, Schwartz J B (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50: 222-239
14. Heykants J, Huang M L, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55 (Suppl.): 13-17
15. Hulst L K, Fleishaker J C, Peters G R, Harry J D, Wright D M, Ward P (1994) Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 55: 378-384
16. Hunt C M, Westerkam W R, Stave G M (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44: 275-283
17. Janssen P A, Niemegeers C J, Awouters F, Schellekens K H, Megens A A, Meert T F (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685-693
18. Kelly D L, Conley R R, Tamminga C A (1999) Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 40: 101-104
19. Le Couteur D G, McLean A J (1998) The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34: 359-373
20. Le Moing J P, Edouard S, Levron J C (1993) Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr 614: 333-339
21. Ludden T M, Beal S L, Sheiner L B (1994) Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22: 431-445
22. McCune J S, Lindley C, Decker J L, Williamson K M, Meadowcroft A M, Graff D, Sawyer W T, Blough D K, Pieper J A (2001) Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41: 723-731
23. Mannens G, Huang M L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21: 1134-1141
24. Miglioli P A, Pivetta P, Strazzabosco M, Orlando R, Okolicsanyi L, Palatini P (1990) Effect of age on single- and multiple-dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 39: 161-164
25. Motulsky, H, Christopoulos, A (2003) Fitting Models to Biological Data Using Linear and Nonlinear Regression. GraphPad Software Inc.
26. Robertson D R, Waller D G, Renwick A G, George C F (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 25: 297-305
27. Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J (1995) Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 122: 223-229
28. Sotaniemi E A, Arranto A J, Pelkonen O, Pasanen M (1997) Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61: 331-339
29. Spina E, Avenoso A, Facciola G, Salemi M, Scordo M G, Ancione M, Madia A G, Perucca E (2001a) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153: 238-243
30. Spina E, Avenoso A, Facciola G, Scordo M G, Ancione M, Madia A (2001b) Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23: 223-227
31. Tamminga W J, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij L F, de Zeeuw R A, Jonkman J H (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55: 177-184
32. Van Beijsterveldt L E, Geerts R J, Leysen J E, Megens A A, Van den Eynde H M, Meuldermans W E, Heykants J J (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53-62
33. Wadelius M, Darj E, Frenne G, Rane A (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62: 400-407
34. Wirshing D A, Marshall B D, Jr, Green M F, Mintz J, Marder S R, Wirshing W C (1999) Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 156: 1374-1379
35. World Health Organization. Manual of the International Classification of Diseases (ICD-10). WHO, Geneva
36. Yoshimura R, Ueda N, Nakamura J (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44: 129-133
37. Zhang X Y, Zhou D F, Cao L Y, Zhang P Y, Wu G Y, Shen Y C (2001) Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 16: 325-330
38. Zourkova A, Hadasova E (2003) Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects. Gen Physiol Biophys 22: 103-113